Alkem Laboratories Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6m14fmjlb9miq5eo60qe4gia.pdf

Key Takeaways


India Business: The Growth Engine

Sandeep Singh: "We have identified around Rs. 200 crore to Rs. 250 crore of cost savings, which are doable in the next 12 months."

U.S. Business: Price Erosion and a Trough Call

Sandeep Singh: "It would sound funny in hindsight, but we do think we have hit rock bottom. I hope I'm correct, so it will certainly improve from now, but could it get worse, we don't know."

Margin Walk and Cost Structure

Rajesh Dubey: "Our guidance of 16% to 16.5%, we feel if this situation is going to continue, then it will be difficult for us to be there and there could be minus side to extent of 100 basis points or something like that."

Cardiology: A Division in Transition


Strategic Initiatives and Pipeline

Sandeep Singh: "Honestly, next 6 to 12 months, we don't see anything dramatically changing that something can kind of turn the tables."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 EBITDA margin15-15.5% on a full-year basis, with second-half margins much higher than the first halfFY23
FY24 EBITDA marginGet back to 18% or 18% plusFY24 onwards
Cost savings realizationRs. 200-250 crore identified, doable; concrete steps to be announcedNext 12 months; announcements in 2-3 months
Other expenses rangeMaintained in the 23% to 24% rangeGoing forward
India business outperformanceCarry forward the outperformance of the domestic franchiseSecond half of FY23
U.S. business trajectoryNo dramatic change expected that can turn the tables; depends on market conditions and approvalsNext 6-12 months

Key Metrics

MetricQ2 FY23
India business revenue growth13% YoY
US business revenue growth-0.9% YoY in rupee terms
Domestic franchise outperformance vs IPM500 bps
Antidiabetic segment growth vs market4x the market growth rate
Gross margin decline4.7% YoY
Price erosion impact on gross margin4.8%
Higher material cost impact on domestic margin1.7% to 1.8%
EBITDA margin, H1 FY2311.6%
EBITDA margin guidance, FY23~15% to 15.5%, revised down from ~16% to 16.5%
EBITDA margin guidance, FY2418% plus, held
Cash generated in the quarter₹400 cr
Cash position, end of September 2022~₹1,350 cr
Identified cost savings target₹200 cr to ₹250 cr, doable in next 12 months
US business share of total revenue25%
US price erosion10% to 15% and probably more than 15%
Chronic division growth~19% to 20%
NRV component of domestic growth5.3% out of total 10% growth
Other expenses as a percentage of revenue24.3%, vs 22.3% in Q2 last year
Acute share of domestic business84%
Chronic share of domestic business16%
Direct import from China10% to 12% of raw material procurement
Indirect China influence on API65% to 70%
Total MR strength~11,000
MRs added, last 12 months~1,000
Fully loaded cost per medical rep₹6.5 lakh to ₹7 lakh (CTC plus operational cost)
MR breakeven time2.5 to 3 years
R&D spend guidance5% to 6% of revenue
Acute MR productivity~₹6.5 lakh
Chronic MR productivity~₹3.8 lakh to ₹3.9 lakh
Domestic growth guidance, next 3 years10% to 12%